



## Berkshire West Area Prescribing Committee Policy Statement

<b>Drug Name</b>	Ranibizumab (Lucentis®)
<b>Indication under review</b>	NICE TA 298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
<b>Policy No:</b>	APC 033
<b>Date of Issue:</b>	January 2014
<b>Review Date:</b>	January 2017
<b>Policy Statement:</b> Ranibizumab is recommended as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia when used in accordance with NICE TA 298, see points below.	
<b>Traffic Light Status</b>	Red
<b>Key Points considered:</b> Ranibizumab is recommended as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia when the manufacturer provides ranibizumab with the discount agreed in the patient access scheme.	
<b>References:</b> NICE TA 298 accessible via <a href="http://www.nice.org.uk/nicemedia/live/14305/65827/65827.pdf">http://www.nice.org.uk/nicemedia/live/14305/65827/65827.pdf</a>	
<b>Date taken to APC:</b>	8 <sup>th</sup> January 2014
<b>Date Ratified by GP MMC on Behalf of the Board:</b>	15 <sup>th</sup> January 2014